• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1. Poster presented at: 28th European Academy of Dermatology and Venereology Congress

home / authors / safety-of-long-term-tildrakizumab-for-plaque-psoriasis-4-year-results-from-resurface-1-poster-presented-at-28th-european-academy-of-dermatology-and-venereology-congress

Articles

New content coming soon.
© 2024 MJH Life Sciences
AJMC®
All rights reserved.